N-(4-nitrobenzoyl)leucine | 65952-92-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(4-nitrobenzoyl)leucine
• 英文别名: 4-methyl-2-(4-nitrobenzamido)-pentanoic acid；N-(4-nitro-benzoyl)-DL-leucine；N-(4-Nitro-benzoyl)-DL-leucin；N-p-nitrobenzoyl-d,l-leucine；4-methyl-2-[(4-nitrobenzoyl)amino]pentanoic acid
• CAS: 65952-92-3
• 化学式: C₁₃H₁₆N₂O₅
• 分子量: 280.28
• InChiKey: FPRYCZWMEUIYAU-UHFFFAOYSA-N

物化性质

• 熔点：
  229-230 °C
• 沸点：
  516.9±35.0 °C(Predicted)
• 密度：
  1.276±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(4-nitrobenzoyl)leucine 在 甲醇 、 氨 作用下， 生成 N-(4-nitro-benzoyl)-leucine amide
  参考文献：
  名称：

  Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil

  摘要：

  The aim of this study was to evaluate the long term effects of the selective Ca2+ blocker verapamil on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. At the end of this clinical trial, plasma ANP levels increased by 16.14% despite the drop in blood pressure while left atrial and ventricular diameters remained unchanged. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical load on the left cardiac chambers but the result of a pharmacological action. These observations also indicate that verapamil exerts part of its antihypertensive action by increasing ANP plasma levels.

  DOI：

  10.1007/bf03190404
• 作为产物：
  描述：

  4-硝基苯甲酰氯 、 alkaline earth salt of/the/ methylsulfuric acid 生成 N-(4-nitrobenzoyl)leucine
  参考文献：
  名称：

  模具NATUR德WASER “schen spezifischen Farbreaktion奥夫α-Aminosäuren

  摘要：

  DOI：

  10.1002/hlca.19430260108

文献信息

• ON THE SEROLOGICAL SPECIFICITY OF PEPTIDES
  作者：K. Landsteiner、J. van der Scheer

  DOI：10.1084/jem.55.5.781

  日期：1932.5.1

  With the idea that studies on the serological properties of peptides may ultimately aid in the understanding of the precipitin reactions of proteins, antigens have been prepared containing aminobenzoylated dipeptides, namely glycyl-glycine, glycyl-d, l-leucine, d, l-leucyl-glycine and d, l-leucyl-d, l-leucine. These four antigens were found to be different serologically, their specificity depending on the structure of the terminal amino acid carrying the free carboxyl group, and to a less degree also on the second amino acid. The results were obtained by means of precipitin and inhibition tests. Analogies to observations on enzyme specificity are discussed.

  带有关于肽的血清学特性研究可能最终有助于理解蛋白质沉淀反应的想法，已经准备了含有氨基苯甲酰化二肽的抗原，即甘氨酰甘氨酸、甘氨酰-d-亮氨酸、d-亮氨酰甘氨酸和d-亮氨酰-d-亮氨酸。这四种抗原在血清学上被发现有所不同，它们的特异性取决于携带游离羧基的末端氨基酸的结构，也在较小程度上取决于第二个氨基酸。这些结果是通过沉淀和抑制试验获得的。与酶特异性观察的类比被讨论。
• The Effects of Substituents on the Geometry of π-π Interactions
  作者：Seth E. Snyder、Bin-Syuan Huang、Yu W. Chu、Huei-Shian Lin、James R. Carey

  DOI：10.1002/chem.201202253

  日期：2012.10.1

  hypothesis that substituents stabilize π–π interactions regardless of their electronic character. To further investigate the origin of substituent effects for π–π interactions, we synthesized and crystallized a series of 4‐substituted benzoyl leucine diethyl amides. Surprisingly, only two of the 4‐substituted compounds formed homochiral dimers. A comparison among the 4‐substituted compounds that crystallized

  我们设计并利用了一种简单的分子识别系统来研究芳族相互作用中的取代基效应。最近，我们发现具有3个和3,5个二取代的苯甲酰亮氨酸二乙基酰胺和不同电子特性的芳香环通过平行的π-π相互作用和两个氢键组织成固态的手性二聚体，但没有这种手性二聚化观察到未取代的情况。这种现象支持这样的假设：取代基无论其电子特性如何都稳定π-π相互作用。为了进一步研究π-π相互作用的取代基效应的起源，我们合成并结晶了一系列4-取代的苯甲酰亮氨酸二乙基酰胺。出人意料的是，只有4个被取代的化合物形成了同手性二聚体。结晶为纯手性二聚体的4取代化合物及其3取代对应物的比较表明，芳环的几何形状彼此之间存在差异，这取决于取代基的电子性质和位置。纯手性二聚体的晶体结构显示出芳环上取代基之间直接，局部相互作用的证据，并且在各个单体中还显示出不等价的二面角。晶体学数据表明，这种“挠曲”可能是各个分子自身取向以最大化各自芳环上的局部偶极子相互作用的结果。
• [EN] NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF<br/>[FR] MODULATEURS DU RÉCEPTEUR NMDA ET PROMÉDICAMENTS, SELS ET UTILISATIONS DE CES DERNIERS
  申请人：NAUREX INC

  公开号：WO2015065891A1

  公开（公告）日：2015-05-07

  Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本文披露了在调节NMDA受体活性方面具有增强效力的化合物。这些化合物被考虑用于治疗疾病和障碍，如学习、认知活动和镇痛，特别是在缓解和/或减轻神经病痛方面。还披露了口服可用的制剂和其他药学上可接受的化合物给药形式，包括静脉注射制剂。
• NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF
  申请人：NAUREX, INC.

  公开号：US20160244485A1

  公开（公告）日：2016-08-25

  Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及增强NMDA受体活性调节效力的化合物。这些化合物可用于治疗疾病和障碍，如学习、认知活动和镇痛，特别是缓解和/或减轻神经病理性疼痛。本发明还揭示了口服制剂和其他药学上可接受的化合物递送形式，包括静脉注射制剂。
• NMDA RECEPTOR MODULATORS
  申请人：Naurex Inc.

  公开号：EP3564256A1

  公开（公告）日：2019-11-06

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  所公开的化合物在调节 NMDA 受体活性方面具有更强的效力。这些化合物可用于治疗疾病和失调，如学习、认知活动和镇痛，特别是减轻和/或减少神经性疼痛。还公开了这些化合物的口服制剂和其他药学上可接受的给药形式，包括静脉注射制剂。